Loading…

What To Do About High Cost Therapies

According to Barlow, around half of those approvals will be in the oncology market, around a third will be in the orphan drugs category, and about an eighth will be in what Barlow called the "quantum leap" category-drugs that will radically alter current treatment paradigms. The timing of...

Full description

Saved in:
Bibliographic Details
Published in:Managed Healthcare Executive 2018-12, Vol.28 (12), p.45-45
Main Author: Hamm, Nicholas
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to Barlow, around half of those approvals will be in the oncology market, around a third will be in the orphan drugs category, and about an eighth will be in what Barlow called the "quantum leap" category-drugs that will radically alter current treatment paradigms. The timing of payments is and will be a problem with these medications. Since most require only a one-time treatment, the cost of treatment is largely front loaded. Another key takeaway from those surveys is that different payers will require different models based on the payer's size and needs. [...]any new plans would need to be tailored to individual payers to some degree.
ISSN:1533-9300
2150-7120